Application of pharmacogenomics and personalized medicine for the care of depression

Chapter 8 - Application of pharmacogenomics and personalized medicine for the care of depression

Published online by Cambridge University Press: 19 October 2021

Keh-Ming Lin ,

Chun-Yu Chen and

Yu-Jui Yvonne Wan

Edited by

Chad E. Beyer and

Stephen M. Stahl

Show author details

Chad E. Beyer: Affiliation:
University of Colorado School of Medicine
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

Remarkable progress notwithstanding, pharmacotherapy for depressive and related conditions, as well as pharmacological intervention of various other psychiatric and medical conditions, has typically ignored the magnitude and clinical relevance of the huge inter-individual variations in pharmacokinetics and pharmacodynamics. Such neglects lead to additional risks of severe and/or unpleasant side effects, medication non-adherence, prolonged periods of titration, suboptimal therapeutic responses, and treatment failures. Advances in pharmacogenomics and computer modeling technologies hold promises for achieving the goals of “personalized” (“individualized”) medicine. However, challenges abound for realizing such goals, including the packaging and interpretation of genotyping results, ethical considerations, financing, economy of scale, inertia against changes in medical practice (innovation diffusion), as well as other infrastructural and organizational issues related to the use of new information.

Type: Chapter
Information: Next Generation Antidepressants
Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
, pp. 119 - 131

DOI: https://doi.org/10.1017/9780511778414 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Fierz, W. 2004, Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends, Med. Sci. Monit., 10(5): 111.Google Scholar

Hallworth, M. 2004, The drugs don’t work: pharmacogenomics – clinical biochemistry’s future? Ann. Clin. Biochem., 41(Pt 4): 260.CrossRef Google Scholar

Ross, J., Schenkein, D., Kashala, O., et al. 2004, Pharmacogenomics, Adv. Anat. Pathol., 11(4): 211.Google Scholar

Haga, S. B., Burke, W. 2004, Using pharmacogenetics to improve drug safety and efficacy, JAMA, 291(23): 2869.CrossRef Google Scholar PubMed

Lin, K.-M., Perlis, R. H., Wan, Y.-J. 2008, Pharmacogenomic strategy for individualizing antidepressant therapy, Dialogues Clin. Neurosci., 10(4): 401.Google Scholar

Bala, M., Zarkin, G. 2004, Pharmacogenomics and the evolution of healthcare: is it time for cost-effectiveness analysis at the individual level? Pharmacoeconomics, 22(8): 495.Google Scholar

Evans, W., Relling, M. 2004, Moving towards individualized medicine with pharmacogenomics, Nature, 429: 464.CrossRef Google Scholar PubMed

Flowers, C., Veenstra, D. 2004, The role of cost-effectiveness analysis in the era of pharmacogenomics, Pharmacoeconomics, 22(8): 481.Google Scholar

Frueh, F., Gurwitz, D. 2004, From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community, Pharmacogenomics, 5(5): 571.Google Scholar

Phillips, K., Veenstra, D., Ramsey, S., Van Bebber, S., Sakowski, J. 2004, Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs, Am. J. Manag. Care, 10(7): 425.Google Scholar

Mordini, E. 2004, Ethical considerations on pharmacogenomics, Pharmacol. Res., 49(4): 375.CrossRef Google Scholar PubMed

Lin, Z., Owen, A., Altman, R. 2004, Genetics: genomic research and human subject privacy, Science, 305(5681): 183.CrossRef Google Scholar PubMed

Voelter-Mahlknecht, S., Mahlknecht, U. 2004, Darwinism and pharmacogenomics: from ‘one treatment fits all’ to ‘selection of the richest’? Trends Mol. Med., 10(5): 208.CrossRef Google Scholar PubMed

Kessler, R. C., McGonagle, K. A., Zhao, S., et al. 1994, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey, Arch. Gen. Psychiatry, 51(1): 8.Google Scholar

Weissman, M. M., Bland, R. C., Canino, G. J., et al. 1996, Cross-national epidemiology of major depression and bipolar disorder, JAMA, 276(4): 293.Google Scholar

Desjarlais, R., Eisenberg, L., Good, B., Kleinman, A. World Mental Health: Problems and Priorities in Developing Countries. New York: Oxford University Press; 1995.Google Scholar

Guze, S. B., Robins, E. L. I. 1970, Suicide and primary affective disorders, Br. J. Psychiatry, 117(539): 437.Google Scholar

Wells, K., Sturm, R., Sherbourne, C., Meredith, L. Caring for Depression: A RAND Study. Cambridge, MA: Harvard University Press; 1996.Google Scholar

Penninx, B. W. J. H., Beekman, A. T. F., Honig, A., et al. 2001, Depression and cardiac mortality: results from a community-based longitudinal study, Arch. Gen. Psychiatry, 58(3): 221.CrossRef Google Scholar PubMed

May, M., McCarron, P., Stansfeld, S., et al. 2002, Does psychological distress predict the risk of ischemic stroke and transient ischemic attack? The Caerphilly Study, Stroke, 33(1): 7.Google Scholar

Judd, L. L., Martin, P. P., Wells, K. B., Rapaport, M. H. 1996, Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population, Am. J. Psychiatry, 153: 1411.Google Scholar

Sherbourne, C. D., Wells, K. B., Hays, R. D. 1994, Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients, Am. J. Psychiatry, 1(51): 1.Google Scholar

APA Task Force. 1985, Tricyclic antidepressants – blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry, Am. J. Psychiatry, 142(2): 155.Google Scholar

Eap, C., Sirot, E., Baumann, P. 2004, Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies, Ther. Drug. Monit., 26(2): 152.CrossRef Google Scholar PubMed

Gram, L., Kragh-Sorensen, P., Kristensen, C., Moller, M., Pedersen, O., Thayssen, P. 1984, Plasma level monitoring of antidepressants: theoretical basis and clinical application, Adv. Biochem. Psychopharmacol., 39: 399.Google Scholar

Mann, K., Hiemke, C., Schmidt, L., Bates, D. 2006, Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care, Ther. Drug. Monit., 28(1): 83.CrossRef Google Scholar PubMed

Kalow, W. 2006, Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine, Pharmacogenomics J., 6(3): 162.Google Scholar

Malhotra, A., Murphy, G., Kennedy, J. 2004, Pharmacogenetics of psychotropic drug response, Am. J. Psychiatry, 161(5): 780.Google Scholar

Weinshilboum, R., Wang, L. 2004, Pharmacogenomics: bench to bedside, Nat. Rev. Drug. Discov., 3(9): 739.Google Scholar

Ingelman-Sundberg, M. 2004, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, Trends Pharmacol. Sci., 25(4): 193.Google Scholar

Lundqvist, E., Johansson, I., Ingelman-Sundberg, M. 1999, Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes, Gene, 226(2): 327.Google Scholar

Mendoza, R., Wan, Y.-J., Poland, R. E., et al. 2001, CYP2D6 polymorphism in a Mexican American population, Clin. Pharmacol. Ther., 70(6): 552.Google Scholar

Wan, Y.-J., Poland, R. E., Han, G., et al. 2001, Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California, Pharmacogenetics, 11(6): 489.Google Scholar

Luo, H.-R., Aloumanis, V., Lin, K.-M., Gurwitz, D., Wan, Y.-J. 2004, Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups, Am. J. Pharmacogenomics, 4(6): 395.CrossRef Google Scholar PubMed

Luo, H.-R., Wan, Y.-J. 2006, Polymorphisms of genes encoding phase I enzymes in Mexican Americans – an ethnic comparison study, Curr. Pharmacogenomics, 4(4): 345.Google Scholar

DeVane, C. L. 1994, Pharmacogenetics and drug metabolism of newer antidepressant agents, J. Clin. Psychiatry, 55 Suppl: 38.Google Scholar

Lessard, E., Yessine, M. A., Hamelin, B. A., O’Hara, G., LeBlanc, J., Turgeon, J. 1999, Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans, Pharmacogenetics, 9(4): 435.Google Scholar

Yin, O., Wing, Y., Cheung, Y., et al. 2006, Phenotype–genotype relationship and clinical effects of citalopram in Chinese patients, J. Clin. Psychopharmacol., 26(4): 367.Google Scholar

Luo, H.-R., Gaedigk, A., Aloumanis, V., Wan, Y.-J. 2005, Identification of CYP2D6 impaired functional alleles in Mexican Americans, Eur. J. Clin. Pharmacol., 61(11): 797.Google Scholar

Luo, H.-R., Poland, R. E., Lin, K.-M., Wan, Y.-J. 2006, Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study, Clin. Pharmacol. Ther., 80(1): 33.Google Scholar

Harper, P. A., Wong, J. M. Y., Lam, M. S. M., Okey, A. B. 2002, Polymorphisms in the human AH receptor, Chem. Biol. Interact., 141(1–2): 161.CrossRef Google Scholar PubMed

Brinkmann, U., Eichelbaum, M. 2001, Polymorphisms in the ABC drug transporter gene MDR1, Pharmacogenomics J., 1(1): 59.Google Scholar

Saito, S., Iida, A., Sekine, A., et al. 2002, Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population, J. Hum. Genet., 47(1): 38.Google Scholar

Baumann, P., Eap, C. B., Muller, W. E., Tillement, J. P. Alpha-Acid Glycoprotein: Genetics, Biochemistry, Physiological Functions and Pharmacology. New York, NY: Alan R. Liss, Inc.; 1989.Google Scholar

Duché, J. C., Urien, S., Simon, N., Malaurie, E., Monnet, I., Barr, J. 2000, Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer, Clin. Biochem., 33(3): 197.Google Scholar

Barker, E. L., Blakely, R. D. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom, F. E. and Kupfer, D. J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995. p. 321.Google Scholar

Nelson, J. C. 1999, A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression, Biol. Psychiatry, 46(9): 1301.Google Scholar

Schatzberg, A. F., Schildkraut, J. J. Recent studies on norepinephrine systems in mood disorders. In: Bloom, F. E. and. Kupfer, D. J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995. p. 911.Google Scholar

Lesch, K. P., Bengel, D., Heils, A., et al. 1996, Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science, 274(5292): 1527.Google Scholar

Greenberg, B. D., McMahon, F. J., Murphy, D. L. 1998, Serotonin transporter candidate gene studies in affective disorders and personality: promises and potential pitfalls, Mol. Psychiatry, 3(3): 186.Google Scholar

Hariri, A. R., Mattay, V. S., Tessitore, A., et al. 2002, Serotonin transporter genetic variation and the response of the human amygdala, Science, 297(5580): 400.Google Scholar

Yu, Y. W., Tsai, S. J., Chen, T. J., Lin, C. H., Hong, C. J. 2002, Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders, Mol. Psychiatry, 7(10): 1115.Google Scholar

Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., Catalano, M. 1998, Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine, Mol. Psychiatry, 3(6): 508.Google Scholar

Pollock, B. G., Ferrell, R. E., Mulsant, B. H., et al. 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression, Neuropsychopharmacology, 23(5): 587.Google Scholar

Serretti, A., Zanardi, R., Rossini, D., Cusin, C., Lilli, R., Smeraldi, E. 2001, Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity, Mol. Psychiatry, 6(5): 586.Google Scholar

Rausch, J. L., Johnson, M. E., Fei, Y. J., et al. 2002, Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome, Biol. Psychiatry, 51(9): 723.Google Scholar

Zanardi, R., Serretti, A., Rossini, D., et al. 2001, Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression, Biol. Psychiatry, 50(5): 323.Google Scholar

Kim, D. K., Lim, S. W., Lee, S., et al. 2000, Serotonin transporter gene polymorphism and antidepressant response, Neuroreport, 11(1): 215.Google Scholar

Yoshida, K., Ito, K., Sato, K., et al. 2002, Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients, Prog. Neuropsychopharmacol. Biol. Psychiatry, 26(2): 383.Google Scholar

Durham, L. K., Webb, S. M., Milos, P. M., Clary, C. M., Seymour, A. B. 2004, The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder, Psychopharmacology, 174(4): 525.Google Scholar

Mundo, E., Walker, M., Cate, T., Macciardi, F., Kennedy, J. L. 2001, The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings, Arch. Gen. Psychiatry, 58(6): 539.Google Scholar

Perlis, R. H., Mischoulon, D., Smoller, J. W., et al. 2003, Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment, Biol. Psychiatry, 54(9): 879.Google Scholar

Konishi, T., Calvillo, M., Leng, A.-S., Lin, K.-M., Wan, Y.-J. 2004, Polymorphisms of the dopamine D2 receptor, serotonin transporter, and GABAA receptor [beta]3 subunit genes and alcoholism in Mexican-Americans, Alcohol, 32(1): 45.Google Scholar

Massat, I., Souery, D., Lipp, O., et al. 2000, A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder, Am. J. Med. Genet., 96(2): 136.Google Scholar

Serretti, A., Lilli, R., Lorenzi, C., Smeraldi, E. 1999, No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders, Psychiatry Res., 86(3): 203.Google Scholar

Bondy, B., Spaeth, M., Offenbaecher, M., et al. 1999, The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia, Neurobiol. Dis., 6(5): 433.Google Scholar

Du, L., Bakish, D., Lapierre, Y. D., Ravindran, A. V., Hrdina, P. D. 2000, Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder, Am. J. Med. Genet., 96: 56.Google Scholar

Tiihonen, J., Kuikka, J., Bergstrom, K., et al. 1995, Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics, Nat. Med., 1(7): 654.Google Scholar

Vandenbergh, D. J., Persico, A. M., Hawkins, A. L., et al. 1992, Human dopamine transporter gene(DAT1) maps to chromosome 5p15.3 and displays a VNTR, Genomics, 14(4): 1104.Google Scholar

Muramatsu, T., Higuchi, S. 1995, Dopamine transporter gene polymorphism and alcoholism, Biochem. Biophys. Res. Commun., 211(1): 28.Google Scholar

Parsian, A., Zhang, Z. H. 1997, Human dopamine transporter gene polymorphism (VNTR) and alcoholism, Am. J. Med. Genet., 74: 480.3.0.CO;2-S>CrossRef Google Scholar PubMed

Sander, T., Harms, H., Podschus, J., et al. 1997, Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium, Biol. Psychiatry, 41(3): 299.Google Scholar

Inada, T., Sugita, T., Dobashi, I., et al. 1996, Dopamine transporter gene polymorphism and psychiatric symptoms seen in schizophrenic patients at their first episode, Am. J. Med. Genet., 67: 406.Google Scholar

Barr, C. L., Xu, C., Kroft, J., et al. 2001, Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder, Biol. Psychiatry, 49(4): 333.Google Scholar

Greenwood, T. A., Alexander, M., Keck, P. E., et al. 2001, Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder, Am. J. Med. Genet., 105: 145.Google Scholar

Schramm, N. L., McDonald, M. P., Limbird, L. E. 2001, The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety, J. Neurosci., 21(13): 4875.Google Scholar

González-Maeso, J., Rodríguez-Puertas, R., Meana, J. J., García-Sevilla, J. A., Guimón, J. 2002, Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha 2A-adrenoceptors, Mol. Psychiatry, 7: 755.Google Scholar

Schittecatte, M., Dumont, F., Machowski, R., et al. 2002, Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha2-adrenergic receptors in depression, Psychiatry Res., 109(1): 1.Google Scholar

Marazziti, D., Baroni, S., Masala, I., et al. 2001, Correlation between platelet alpha(2)-adrenoreceptors and symptom severity in major depression, Neuropsychobiology, 44(3): 122.Google Scholar

Zill, P., Baghai, T. C., Engel, R., et al. 2003, Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response, Am. J. Med. Genet., 120B(1): 85.Google Scholar

Szegedi, A., Rujescu, D., Tadic, A., et al. 2004, The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression, Pharmacogenomics J., 5(1): 49.Google Scholar

Sabol, S. Z., Hu, S., Hamer, D. 1998, A functional polymorphism in the monoamine oxidase A gene promoter, Hum. Genet., 103(3): 273.Google Scholar

Kunugi, H., Ishida, S., Kato, T., et al. 1999, A functional polymorphism in the promoter region of monoamine oxidase-A gene and mood disorders, Mol. Psychiatry, 4(4): 393.CrossRef Google Scholar PubMed

Ibanez, A., Perez de Castro, I., Fernandez-Piqueras, J., Saiz-Ruiz, J. 2000, Association between the low-functional MAO-A gene promoter and pathological gambling, Am. J. Med. Genet., 96: 464.Google Scholar

Bellivier, F., Leboyer, M., Courtet, P., et al. 1998, Association between the tryptophan hydroxylase gene and manic-depressive illness, Arch. Gen. Psychiatry, 55(1): 33.Google Scholar

Nielsen, D. A., Virkkunen, M., Lappalainen, J., et al. 1998, A tryptophan hydroxylase gene marker for suicidality and alcoholism, Arch. Gen. Psychiatry, 55(7): 593.Google Scholar

Serretti, A., Lorenzi, C., Cusin, C., et al. 2003, SSRIs antidepressant activity is influenced by Gβ3 variants, Eur. Neuropsychopharmacol., 13(2): 117.Google Scholar

Murphy, G. M., Kremer, C., Rodrigues, H., Schatzberg, A. F. 2003, The apolipoprotein E e4 allele and antidepressant efficacy in cognitively intact elderly depressed patients, Biol. Psychiatry, 54(7): 665.Google Scholar

Russo-Neustadt, A. A., Chen, M. J. 2005, Brain-derived neurotrophic factor and antidepressant activity, Curr. Pharm. Des., 11(12): 1495.Google Scholar

Lan, T., Loh, E., Wu, M., et al. 2008, Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics, Mol. Psychiatry, 13(12): 1129.Google Scholar

Lin, C., Wang, Y., Chen, J., et al. 2008, Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data, Comput. Methods Programs Biomed., 91(2): 91.Google Scholar

Serretti, A., Smeraldi, E. 2004, Neural network analysis in pharmacogenetics of mood disorders, BMC Med. Genet., 5(1): 27.Google Scholar

Sproule, B., Naranjo, C., Türksen, I. 2002, Fuzzy pharmacology: theory and applications, Trends Pharmacol. Sci., 23(9): 412.Google Scholar

Lesko, L., Woodcock, J. 2004, Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective, Nat. Rev. Drug. Discov., 3(9): 763.Google Scholar